A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

NCT06864143 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1320

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
SARS-CoV-2

Interventions

BIOLOGICAL: mRNA-1083 Composition 1 Dose A Lot A
BIOLOGICAL: mRNA-1083 Composition 1 Dose A Lot B
BIOLOGICAL: mRNA-1083 Composition 1 Dose B
BIOLOGICAL: mRNA-1083 Composition 1 Dose C
BIOLOGICAL: mRNA-1083 Composition 2 Dose A
BIOLOGICAL: mRNA-1083 Composition 2 Dose B
BIOLOGICAL: mRNA-1083 Composition 3 Dose A
BIOLOGICAL: mRNA-1083 Composition 3 Dose B
BIOLOGICAL: Influenza Vaccine
BIOLOGICAL: COVID-19 Vaccine
BIOLOGICAL: Investigational Influenza Vaccine
BIOLOGICAL: Investigational COVID-19 Vaccine Lot A
BIOLOGICAL: Investigational COVID-19 Vaccine Lot B

Sponsor

ModernaTX, Inc.